The State of the Gene Therapy Industry (2024–2026): Why Analytical Development Has Never Mattered More
Between 2024 and 2026, gene therapy teams across Europe have been operating in a tougher environment: constrained budgets, consolidation, and a sharper focus on achieving more with less. At the same time, late-stage programmes are advancing, elevating expectations around analytical rigor, QC readiness, and regulatory credibility. In short, the bar has risen, resources haven’t, and analytical development now sits at the centre of whether programmes progress on time or stall.
The 7th Gene Therapy Analytical Development Summit Europe provides an important anchor in this shifting landscape, giving analytical, QC, and CMC teams a rare opportunity to gain practical insight into the road ahead, understand how peers are adapting, and receive regulator-informed guidance directly from the MHRA.
Developers know what’s at stake. If your analytical package doesn’t convincingly demonstrate identity, safety, potency, and consistency, you invite rework, inspection risk, and delays that drain cash and momentum. That’s why the European community is seeking clarity on qualification versus validation expectations in early phases, credible potency assurance by Phase II/III, and comparability strategies that withstand scrutiny.
Funding Uncertainty Meets Late-Stage Momentum
Budget restrictions have changed how teams build their toolbox. Many groups are reducing reliance on expensive “black box” kits or outsourced panels in favour of in-house methods and raw materials, ringing every drop of value from existing platforms. Yet the clinical narrative isn’t bleak; several European programmes and approvals have created renewed confidence, with companies advancing towards pivotal studies and approvals. This mixed picture of fiscal constraint plus clinical progress explains today’s emphasis on efficient, defensible analytics.
Regulators Are Asking for More Earlier
European developers aiming for both EMA and FDA markets are facing tightened expectations. There’s no one size fits all path for gene therapy analytics; regulators expect a coherent matrix of assays aligned to the product’s mechanism, lifecycle, and risk. Teams are being pressed to justify assay readiness even at Phase I, to plan potency assurance strategies early (not just a late-stage scramble), and to anticipate how their QC story will read as they move into PPQ and BLA/MAA.
It’s not simply about running “more assays.” It’s about designing the right, fit for purpose panel, reducing redundancy, and building layered control strategies that tame variability, particularly for complex cell based potency methods.
Why Better Analytics Are the Foundation of Safety, Potency, and Approval
Robust analytics prove you’ve made what you intended, that it remains intact, does what it should, and is consistently manufactured to high-quality standards.
For gene therapy, this spans characterisation of empty/partial/full capsids, impurity profiling, degradation pathways, genome integrity, functional activity, and more. If you can’t defend that package, you risk clinical holds or post-submission questions that are costly to resolve. Getting analytics right is therefore inseparable from speed to patients and speed to market.
Europe’s Unique Moment To Align
In 2026, the 7th Gene Therapy Analytical Development Summit Europe convenes the region’s analytical development, QC, CMC, and MSAT leaders in London (5–7 May). These experts are coming together for a deep dive on potency assurance, product characterisation, comparability, and regulatory alignment with MHRA guidance. This is Europe’s dedicated analytical development meeting; it exists to build shared understanding, reduce uncertainty, and help teams benchmark “what good looks like” from preclinical through late stage.
Expect practical, case-driven content, including:
- “Good enough” potency panels
- Solving hard-to-transduce AAV serotypes
- High resolution characterisation
- NGS realities
- Tech transfers
- Regulatory scenario workshop where a hypothetical QC strategy is “stress tested” live with MHRA input
These sessions are designed to surface what triggers a green light versus a red flag and how to future proof your own strategy.
Why Now and Why Together
Teams are under pressure to deliver phase-appropriate rigor without over-engineering. Sharing what works and where corners cannot be cut accelerates everyone.
That’s exactly what this community-led meeting provides: candid benchmarking; regulator-informed signals; and the latest thinking from organisations like Orchard Therapeutics, UCB, MeiraGTx, iBET Bio, AAVantgarde, Complement Therapeutics, and the MHRA.
Ready to align with Europe’s analytical leaders? Join the community to benchmark your approach, pressure test your potency and QC strategy, and leave confident about your path to Phase II/III and beyond.